Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients

Kaleb D Michaud, Gene Wallenstein, Frederick Wolfe

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective. To examine predictors of progression of disability in rheumatoid arthritis (RA), as measured by the Health Assessment Questionnaire disability index (HAQ), and to determine rates of progression during biologic treatment. Methods. We followed 18,485 RA patients for up to 11 years (mean 3.7 years) in a longitudinal study of RA outcomes. Patients were characterized as having moderate or severe RA versus less severe RA at study entry. Annualized progression rates were determined in multivariable analyses using generalized estimating equations. Results. Although all of the demographic and severity characteristics were associated with baseline differences in HAQ score, progression was only associated with age, comorbidity, initial severity, and treatment. HAQ score increased fastest in patients ages >65 years (0.031; 95% confidence interval [95% CI] 0.028, 0.034). HAQ progression was independently associated with the presence of baseline cardiovascular disease, hypertension, diabetes mellitus, and the number of comorbid conditions. Annualized progression rates were greater in patients with mild to inactive RA (0.021; 95% CI 0.019, 0.023) than in moderate to severe RA (0.003; 95% CI 0.001, 0.006). The overall progression rate during biologic treatment was 0.008 (95% CI 0.005, 0.011); for patients with moderate to severe RA, the rate was 0.001 (95% CI-0.005, 0.003). Conclusion. Age and comorbidity are important predictors of the rate of loss of functional status, and have a stronger effect on HAQ progression than does biologic treatment. There is little difference in progression rates among biologics. Patients with more severe RA progress less than those with less severe RA, a possible function of regression to the mean.

Original languageEnglish (US)
Pages (from-to)366-372
Number of pages7
JournalArthritis Care and Research
Volume63
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

ametantrone
Longitudinal Studies
Rheumatoid Arthritis
Health
Confidence Intervals
Therapeutics
Comorbidity
Surveys and Questionnaires
Biological Products
Diabetes Mellitus
Cardiovascular Diseases
Demography
Hypertension

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis : A longitudinal study of 18,485 patients. / Michaud, Kaleb D; Wallenstein, Gene; Wolfe, Frederick.

In: Arthritis Care and Research, Vol. 63, No. 3, 01.03.2011, p. 366-372.

Research output: Contribution to journalArticle

@article{c5fd2cdb2dcf4f81abed23438a50b22f,
title = "Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients",
abstract = "Objective. To examine predictors of progression of disability in rheumatoid arthritis (RA), as measured by the Health Assessment Questionnaire disability index (HAQ), and to determine rates of progression during biologic treatment. Methods. We followed 18,485 RA patients for up to 11 years (mean 3.7 years) in a longitudinal study of RA outcomes. Patients were characterized as having moderate or severe RA versus less severe RA at study entry. Annualized progression rates were determined in multivariable analyses using generalized estimating equations. Results. Although all of the demographic and severity characteristics were associated with baseline differences in HAQ score, progression was only associated with age, comorbidity, initial severity, and treatment. HAQ score increased fastest in patients ages >65 years (0.031; 95{\%} confidence interval [95{\%} CI] 0.028, 0.034). HAQ progression was independently associated with the presence of baseline cardiovascular disease, hypertension, diabetes mellitus, and the number of comorbid conditions. Annualized progression rates were greater in patients with mild to inactive RA (0.021; 95{\%} CI 0.019, 0.023) than in moderate to severe RA (0.003; 95{\%} CI 0.001, 0.006). The overall progression rate during biologic treatment was 0.008 (95{\%} CI 0.005, 0.011); for patients with moderate to severe RA, the rate was 0.001 (95{\%} CI-0.005, 0.003). Conclusion. Age and comorbidity are important predictors of the rate of loss of functional status, and have a stronger effect on HAQ progression than does biologic treatment. There is little difference in progression rates among biologics. Patients with more severe RA progress less than those with less severe RA, a possible function of regression to the mean.",
author = "Michaud, {Kaleb D} and Gene Wallenstein and Frederick Wolfe",
year = "2011",
month = "3",
day = "1",
doi = "10.1002/acr.20405",
language = "English (US)",
volume = "63",
pages = "366--372",
journal = "Arthritis and Rheumatism",
issn = "2151-4658",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis

T2 - A longitudinal study of 18,485 patients

AU - Michaud, Kaleb D

AU - Wallenstein, Gene

AU - Wolfe, Frederick

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objective. To examine predictors of progression of disability in rheumatoid arthritis (RA), as measured by the Health Assessment Questionnaire disability index (HAQ), and to determine rates of progression during biologic treatment. Methods. We followed 18,485 RA patients for up to 11 years (mean 3.7 years) in a longitudinal study of RA outcomes. Patients were characterized as having moderate or severe RA versus less severe RA at study entry. Annualized progression rates were determined in multivariable analyses using generalized estimating equations. Results. Although all of the demographic and severity characteristics were associated with baseline differences in HAQ score, progression was only associated with age, comorbidity, initial severity, and treatment. HAQ score increased fastest in patients ages >65 years (0.031; 95% confidence interval [95% CI] 0.028, 0.034). HAQ progression was independently associated with the presence of baseline cardiovascular disease, hypertension, diabetes mellitus, and the number of comorbid conditions. Annualized progression rates were greater in patients with mild to inactive RA (0.021; 95% CI 0.019, 0.023) than in moderate to severe RA (0.003; 95% CI 0.001, 0.006). The overall progression rate during biologic treatment was 0.008 (95% CI 0.005, 0.011); for patients with moderate to severe RA, the rate was 0.001 (95% CI-0.005, 0.003). Conclusion. Age and comorbidity are important predictors of the rate of loss of functional status, and have a stronger effect on HAQ progression than does biologic treatment. There is little difference in progression rates among biologics. Patients with more severe RA progress less than those with less severe RA, a possible function of regression to the mean.

AB - Objective. To examine predictors of progression of disability in rheumatoid arthritis (RA), as measured by the Health Assessment Questionnaire disability index (HAQ), and to determine rates of progression during biologic treatment. Methods. We followed 18,485 RA patients for up to 11 years (mean 3.7 years) in a longitudinal study of RA outcomes. Patients were characterized as having moderate or severe RA versus less severe RA at study entry. Annualized progression rates were determined in multivariable analyses using generalized estimating equations. Results. Although all of the demographic and severity characteristics were associated with baseline differences in HAQ score, progression was only associated with age, comorbidity, initial severity, and treatment. HAQ score increased fastest in patients ages >65 years (0.031; 95% confidence interval [95% CI] 0.028, 0.034). HAQ progression was independently associated with the presence of baseline cardiovascular disease, hypertension, diabetes mellitus, and the number of comorbid conditions. Annualized progression rates were greater in patients with mild to inactive RA (0.021; 95% CI 0.019, 0.023) than in moderate to severe RA (0.003; 95% CI 0.001, 0.006). The overall progression rate during biologic treatment was 0.008 (95% CI 0.005, 0.011); for patients with moderate to severe RA, the rate was 0.001 (95% CI-0.005, 0.003). Conclusion. Age and comorbidity are important predictors of the rate of loss of functional status, and have a stronger effect on HAQ progression than does biologic treatment. There is little difference in progression rates among biologics. Patients with more severe RA progress less than those with less severe RA, a possible function of regression to the mean.

UR - http://www.scopus.com/inward/record.url?scp=84858028256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858028256&partnerID=8YFLogxK

U2 - 10.1002/acr.20405

DO - 10.1002/acr.20405

M3 - Article

C2 - 21080449

AN - SCOPUS:84858028256

VL - 63

SP - 366

EP - 372

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

SN - 2151-4658

IS - 3

ER -